As revealed by Table 2, the AUC0–72 for CIS by IV administration of 2CIS2 was 35,030.66 ± 3817.20 ng/h/mL, which was 1.12-, 0.98-, and 1.05-fold, respectively, higher than those for the SC administration of 2CIS2 (3,1398.67 ± 1941.69 ng/h/mL), 2DTX2/CIS2 (35,684.62 ± 2738.70 ng/h/mL), and P13L0.15O1.52D2C2 (33,273.03 ± 6790.87 ng/h/mL). The gene discussed is SOCS2; the disease is in situ carcinoma.